Navigation Links
Oridion Expands its Presence in the Pre-hospital Market with an OEM Partnership with a leading Defibrillator Manufacturer
Date:5/25/2009

Oridion today announced that it signed an OEM agreement with a leading global manufacturer of resuscitation devices. With this agreement, Oridion Microstream® capnography solutions will be incorporated into a defibrillator monitoring system at a future date.

Jerusalem/Needham, MA (PRWEB) May 26, 2009 -- Oridion Systems Ltd. (SIX Swiss Exchange: ORIDN) today announced that it signed an OEM agreement with a leading global manufacturer of resuscitation devices. With this agreement, Oridion Microstream® capnography solutions will be incorporated into a defibrillator monitoring system at a future date.

The patented Microstream® end tidal carbon dioxide (etCO2) measurement technologies and proprietary breath sampling (FilterLine®) products improve patient safety by providing the earliest assessment of a patient's ventilatory status in both intubated and non intubated patients.

Researchers have shown that capnography is an important tool during emergency applications. It has, for example, proven far superior in recognizing misplaced endotracheal tubes when compared to traditional clinical subjective evaluations(1). Other studies show that etCO2 levels should be monitored during CPR (Cardiopulmonary resuscitation) and should be regarded as having important prognostic value in predicting the outcome of resuscitative efforts(2).

Gerry Feldman, President of Oridion Systems Ltd., said: "We are very proud to have entered into this agreement. It demonstrates further recognition of the value Microstream respiratory solutions bring to the emergency care market. This alliance combines our newest partner's formidable strength in defibrillator/monitor products with Oridion global leadership in capnography technology in order to improve patient safety and patient outcomes."

(1) Silvestri S, Ralls GA, Krauss B, et al. The effectiveness of out of hospital use of continuous end tidal carbon dioxide monitoring on the rate of unrecognized misplaced intubation within a regional emergency medical services system. Ann Emerg Med 45(5):497 503, 2005.
(2) Miran K, Miljenko K, et al. Partial pressure of end tidal carbon dioxide successful predicts cardiopulmonary resuscitation in the field: a prospective observational study, Critical Care 2008, 12:R115 (doi:10.1186/cc7009)

For further Oridion information please contact
Alan Adler, Chairman and Chief Executive Officer
Walter Tabachnik, Chief Financial Officer
Elena Gerberg, Investor Relations

website: www.oridion.com
e-mail: investor (at) oridion (dot) com
phone: +972 2 589 9159
address: Oridion Systems Ltd., P.O. Box 45025, 91450 Jerusalem, Israel

About Oridion
Oridion Systems Ltd. (www.oridion.com) is a global medical device company specializing in patient safety monitoring. The Company operates through wholly owned subsidiaries in the United States, Europe, and Israel.

Oridion develops proprietary medical devices and patient interfaces, based on its patented Microstream® technologies, for the enhancement of patient safety through the monitoring of the carbon dioxide (CO2) in a patient's breath. These products provide effective, proven airway management and are used in various clinical environments, including procedural sedation, pain management, operating rooms, critical care units, post-anesthesia care units, emergency medical services, transport, alternate care and other settings where patients' ventilation may be compromised and at risk.

Certain statements made herein that are not historical are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words "estimate" "project" "intend" "expect" "believe" and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties. Many factors could cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, among others, our ability to maintain profits, the market demands for our Capnography products, our ability to focus our team on the Capnography business, changes in general economic and business conditions, inability to maintain market acceptance to the Company's products, inability to timely develop and introduce new technologies, products and applications, rapid changes in the market for the Company's products, loss of market share and pressure on prices resulting from competition, introduction of competing products by other companies, inability to manage growth and expansion, loss of key OEM partners, inability to attract and retain qualified personnel, inability to protect the Company's proprietary technology.

Furthermore, this press release does not constitute an offer to sell or a solicitation of an offer to buy any securities. The Company's shares issued have not been, and will not be, registered under the US Securities Act of 1933, as amended (the "Securities Act"), or under any of the relevant Securities Laws of any state of the United States. The Company's shares may not be offered, sold or delivered, directly or indirectly, to, or for, the account of any US person (as defined in regulation S under the Securities Act) in or into the United States, or by use of the US mail, or by any means or instrumentality of United States interstate commerce, absent registration, or an exemption from registration under the Securities Act.

###

Read the full story at http://www.prweb.com/releases/Microstream/Capnography/prweb2458784.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Oridion Receives FDA 510(k) Clearance for Capnostream(TM)20 Monitor With Integrated Pulmonary Index(TM)
2. Oridion Signs Strategic Development and Marketing Agreement with Global Healthcare Company
3. Oridion Introduces New Smart Capnography System for Improved Patient Safety
4. MxSecure Expands Offerings with M*Modal Speech Recognition Solution
5. Viant Expands Relationship With HMA for Improved Healthcare Access in AZ
6. moksha8 Expands Alliance With Roche to Commercialize $200 Million of Products in Brazil and Mexico
7. Peter MacCallum Cancer Centre Expands Cancer Research Efforts with Automation Tool from Caliper Life Sciences
8. Water Street Healthcare Partners Expands Team With Senior Investment Professionals
9. Theravive.com Expands Values Counseling and Therapy Into Michigan, Florida, and Washington State
10. Shire Expands Gastrointestinal Patient Assistance Program for Uninsured or Unemployed Americans
11. Offit Kurman Expands into Bethesda
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
Breaking Medicine Technology: